Get past bacterial resistance with ocular antibiotic armamentarium

Article

Continued evolution in the landscape of bacterial resistance and antimicrobial agents is mandating careful prescribing of anti-infective medications to optimize success in prophylactic and therapeutic indications and to minimize future problems associated with pathogen resistance.

"The first successful clinical use of an antibiotic was 80 years ago and was for an ocular infection. We've come a long way since then in developing new antibiotics with new mechanisms of action, but we have also managed to use these agents in ways where many no longer work," noted Dr. May, who is in private practice in northern Mississippi and serves as adjunct faculty for Southern College of Optometry, Memphis, TN.

Dr. May explained that subtherapeutic and long-term dosing are both culprits in promoting bacterial resistance so that it is important to not taper antibiotic treatment regimens and use only a short-term course when prescribing an anti-infective agent as surgical prophylaxis.

Antimicrobial choices

Currently, fluoroquinolones are the most widely used anti-infective agents for ocular infections. However, older peptide antibiotics, bacitracin and polymixin B, and folic acid synthesis inhibitors, such as sulfacetamide and trimethoprim, can be a useful and cost-effective option in appropriately selected situations.

Proper prescribing depends on understanding the spectrum of activity of the various agents and whether they are bacteriostatic or bactericidal.

The folic acid synthesis inhibitors are bacteriostatic agents that have good activity against gram-positive bacteria. However, these agents should not be used in anyone with known sulfonamide sensitivity or in the management of more serious infections because they are bacteriostatic agents.

Recent Videos
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
Ali Tafreshi sits down with Optometry Times to discuss Topcon's "Healthcare from the Eye" initiative.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
OptiLIFT in action: Dr. Julie McLaughlin's experience with the new device
© 2025 MJH Life Sciences

All rights reserved.